PR98774

ABERDEEN, Scotland and SINGAPORE, Nov. 14, 2022 /PRNewswire=KYODO JBN/ --

- Substantial investment of USD119 million achieved by TauRx through a warrants

exercise triggered by the announcement of LUCIDITY results in October,

supporting HMTM regulatory submissions in UK, US and Canada, and preparation

for market availability

- Shareholder commitment to TauRx represents a significant success story for

UK-based life sciences research and development in areas of great unmet medical

need

- TauRx will present the Phase 3 findings at the Clinical Trials in Alzheimer's

Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco

TauRx Pharmaceuticals Ltd is a global leader in tau-based research in

Alzheimer's disease (AD). Pathological aggregation of Tau correlates with

clinical disease severity and brain atrophy. It is a hallmark of the disease

recognised as an important potential target for treating AD. HMTM is an oral

tau aggregation inhibitor, targeting this underlying pathology.

Glenn Corr, Chief Operating Officer and Chief Business Officer said: "We

appreciate the continued support of our shareholders as evidenced by their

exercise of warrants. This represents a firm commitment to our mission – 'To

discover, develop, and commercialise innovative products for the diagnosis and

treatment of neurodegenerative diseases caused by protein aggregation'. Beyond

funding regulatory submissions in the UK, US and Canada, this investment will

also advance development plans for regulatory approval in China."

The positive outcome of this funding round, with more than 99% of warrants

exercised, was triggered by the announcement of Phase 3 LUCIDITY (NCT03446001)

topline data and adds to USD64 million raised in 2021 through a previous rights

issue.

TauRx, supported by its group of strategic advisors, are moving forward in the

regulatory submission process. This represents a monumental success for

UK-based life sciences research and has potential to deliver a much-needed

additional treatment option for the millions of people with Alzheimer's.

On Monday, 14 November, TauRx will present at the LSX Investival conference in

London and attend the Jefferies Healthcare conference later in the week.

Results from the LUCIDITY trial will be presented at the Clinical Trials on

Alzheimer's Disease (CTAD) conference in San Francisco on 30 November.

ABOUT LUCIDITY

LUCIDITY is the only late-stage clinical trial specifically targeting the tau

pathology of Alzheimer's. Aggregation of abnormal tau protein is one of the

hallmark pathologies.

https://www.luciditytrial.com

ABOUT TAURx PHARMACEUTICALS LTD

The TauRx group of companies was established in 2002 in Singapore, continuing a

partnership with the University of Aberdeen, with primary research facilities

and operation based in Aberdeen, UK. The company has dedicated the past two

decades to developing treatments and diagnostics for Alzheimer's and other

neurodegenerative diseases due to protein aggregation pathology.

TauRx plans to submit HMTM for regulatory approval in the UK, US and Canada in

2023, with other territories to follow, in line with its overall plans to

commercialise HMTM and pursue clinical trials in other related

neurodegenerative diseases.

https://www.taurx.com

LinkedIn: https://www.linkedin.com/company/taurx-therapeutics

Youtube: https://www.youtube.com/user/TauRxTherapeutics

Twitter: https://twitter.com/TauRx

Source: TauRx Pharmaceuticals Ltd